Arcutis anticipates net product revenue of between $455 million and $470 million for the full year 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Is ARQT a Buy, Before Earnings?
- Arcutis Biotherapeutics presents quality of life, long-term data on ZORYVE
- Arcutis Biotherapeutics: Buy Rating Affirmed Amid FDA Approval and Strategic Growth Initiatives
- Arcutis Biotherapeutics announces FDA approval of ZORYVE cream sNDA
- Arcutis Biotherapeutics announces new Zoryve data at EADV congress